

The Role of Aloe Vera Extract on Bacterial Count in the Urine of Albino Rats Infected with *Proteus Mirabilis* and its Comparison with Ciprofloxacin

SHAZIA ASIM¹, SAJIDA MALIK², HUMAIRA SIDDIQUE³, WARDAH SIDDIQUE⁴

ABSTRACT

Proteus mirabilis, a Gram-negative pathogen, is most frequently associated with urinary tract infections. When attached to urinary tract, this pathogen infects kidney more commonly than other pathogens. It may cause fever, bacteremia, acute pyelonephritis, and renal stones. If there is one-hundred thousand colony forming units per milliliter in the urine, this is indicative of a urinary tract infection. Aloe vera has been documented to have an important antimicrobial activity as it efficiently kills or significantly decrease or remove the growth of *Klebsiella pneumoniae*, *Staphylococcus aureus* and *Escherichia coli* etc. The purpose of this study was to understand the role of Aloe vera in *Proteus mirabilis* induced urinary tract infection and its comparison with Ciprofloxacin, considering bacterial count as a marker of infection in order to determine antimicrobial activity of Aloe vera. Five groups of 50 female albino rats, containing 10 in each group were used. Through artificial means, UTI was introduced in all animals. First group was kept as experimental control. The positive control group was given Ciprofloxacin. Three different doses of aqueous extract of Aloe vera whole leaf were used in group rest of three groups. Bacterial count in urine was calculated on day 0, 1, 5, 10 and 15, in advance and subsequent to the administration of Ciprofloxacin and Aloe vera extract (in three different doses). Assessment for bacterial count in urine among three groups showed that, at low doses Aloe vera had insignificant effect, but had modest antibacterial outcome at intermediate dose (p-value 0.037), while at a high dose the result was nearly equivalent with Ciprofloxacin (p-value 0.970).

Conclusion: The reduction in urinary bacterial count with Aloe vera extract is comparable to ciprofloxacin indicating its activity against *Proteus mirabilis*. It is a potential therapeutic remedy in patients where Ciprofloxacin cannot be used, but it takes longer time to exert its effect.

Keyword: Aloe vera, Urinary Tract Infections (UTI), Urine bacterial count, Ciprofloxacin

INTRODUCTION

UTIs due to *Proteus mirabilis* are well known and they significantly damage kidneys⁽¹⁾. Drugs available for *Proteus* infection include co-trimoxazole (TMP/SMZ), third generation cephalosporin, fluoroquinolones and gentamicin². Ciprofloxacin (fluoroquinolones) is a known antibacterial drug for its action against gram-negative pathogen responsible for Urinary Tract Infections. Fluoroquinolones has shown a high incidence of resistance against urinary pathogens. This trend towards developing resistance against pathogen demands to re-assess the treatment for UTI³.

Common name for Aloe vera in Pakistan is *Quarganda*⁴. Phytochemical analysis of Aloe vera showed approximately 75 nutrients and 200 active compounds containing sugar, vitamins, amino acids,

minerals, enzymes, saponins, anthraquinones and salicylic acid⁵. Aloe vera gel efficiently kills or reduces the growth of *Streptococcus pyogenes*, *Staphylococcus aureus*, *Klebsiella pneumoniae* and *Escherichia coli*⁶. Anthraquinones and saponin present in whole leaf of Aloe vera have expressed direct antibacterial activity. The gel of Aloe vera contains polysaccharides, which are responsible for indirect antibacterial activity through stimulation of phagocytic leucocytes⁷. In one of the studies, Aloe vera inhibited the growth of 8 out of 14 bacteria, and this activity as determined from the zone of inhibition, was most prominent against *Alcaligenes faecalis* and *Proteus mirabilis*⁸.

The probable anti-microbial mechanism of Aloe vera is because of the synergistic effects of various bioactive constituents, working through a number of modes⁹. Among these constituents, the phenol compounds i.e., Cinnamic acid; Pyrocatechol, Ascorbic acid and *p*-coumaric acid have shown maximum antibacterial activity by several mechanisms. For example, they act by disturbing cell membranes, destroying proteins of pathogens or by

¹Assistant Professor, Department of Pharmacology, Lahore Medical & Dental College, Lahore

²Assoc Prof Pharmacology, Allama Iqbal Medical College, Lahore

³House surgeon, Punjab Dental Hospital, Lahore

⁴Sr lecturer Pharmacology, Lahore Medical & Dental College,

Correspondence to Dr. Shazia Asim, Email: shaziasim33@yahoo.com

inhibiting glucose uptake and ATP assembly¹⁰. They may also act by prolonging the lag phase of the micro-organisms or by restricting the enzymatic activity of the bacteria, in addition the immune system may also be tempered. Acemannan, another constituent of Aloe vera, may interfere the bacterial binding with epithelial cell⁶.

Antibiotic resistance, worldwide is increasing to an alarming level and the trials and researches are being made to find out different antibacterial treatments. Aloe vera and its components can be used as a substitute or adjunctive therapy⁶. This study was designed to assess the efficacy of Aloe vera as a substitute treatment for infections with *Proteus mirabilis* by analyzing the fall in bacterial count in the urine of albino rats and comparing it with ciprofloxacin.

MATERIAL AND METHODS

In this experimental study various strengths of whole leave Aloe vera aqueous extract and Ciprofloxacin were given to 5 groups of rats for fifteen days. The change in the urinary bacterial count was observed at different intervals to assess and compare the antimicrobial activity of these strengths. Randomized control experimental study that was conducted in Pharmacology and Pathology Department of PGMI, Lahore, Pakistan. Female albino rats, 50 in number, weighing within range of 150 and 300 gm, were obtained and acclimatized before starting the research work. *Proteus mirabilis* was arranged from AFIP. Artificial UTI was introduced in all 50 rats. Infection was confirmed by culture and after confirmation through simple random balloting these rats was divided into 5 groups of 10 animals.

Group 1 (Control group): no treatment was given

Group 2: 30 mg/kg of ciprofloxacin was given B.D for 15 days¹¹.

Group 3, 4, 5: rats in these groups were given increasing doses of Aloe vera 25, 50 and 100 ppm respectively B.D for 15 days¹².

Whole leave extract of fresh Aloe leaves (250gm) was prepared by blending Aloe vera leave and filtering them through sieve. Working dilution of 25,000ppm (stock solution) was prepared⁽¹²⁾ and from this stock solution, three required dilutions were made i.e., 25 ppm, 50ppm & 100 ppm.

Proteus mirabilis, in dose of 5×10^7 bacteria/ml (in phosphate buffer saline solution) was adjusted with the help of optical density method according to McFarland scale¹³.

Rats were anesthetized and infused slowly with 0.5cc of bacterial suspension of *Proteus mirabilis*, through urethra by means of sterile polyethylene catheter⁽¹⁴⁾. Morning urinary samples of all rats were

collected 2 days after inoculation of infection that was considered day 1 and later on days 5, 10 and 15⁽¹⁵⁾. After 2 days of inoculation confirmation of urinary infection with *Proteus mirabilis* was done⁽¹⁶⁾, and according to dosing schedule (mentioned earlier) treatment was started.

RESULTS AND DISCUSSION

Statistical Package for Social Sciences (SPSS) version 18.0 was used. ANOVA and Tukey's test for post hoc analysis were used. The difference was considered statistically significant if the 'p' value was < 0.05.

The data collected during this work indicated that Aloe vera possess antibacterial activity which depends on both factors i.e. dose of the extract and duration of treatment. In this research the bacterial count was studied among the groups at different stages (days). Observation was made that the bacterial count constantly increased through research time in the group 1 which was not given any treatment. This was comparable to group 3 in which low dose of aloe vera was administered where the rise in bacterial count was observed in the same pattern (as with group 1) till day 15. In group 4 (given 50 ppm), a noteworthy drop in bacterial count was observed when compared with group 1 on day 15 with p value 0.001. In group 5 (given 100 ppm), the bacterial count dropped till last day, with p-values of 0.001. This observation proposed that by increasing the dose of Aloe vera, there was a fall in bacterial count and in highest dose i.e. 100ppm this plant showed a better antibacterial action against *Proteus mirabilis*. In another research it was stated that Aloe vera showed a significant in vitro antibacterial activity and it was particularly active against *Proteus mirabilis*⁸. This is close to this in vivo work, as Aloe vera, in high dose, reduced the total number of urinary pathogen.

With Ciprofloxacin (group 2), however the bacterial counts started decreasing from day 1 and decrease levels of 2102 ± 3338 were achieved on last day i.e. day 15. A significantly low number of bacteria were found in group 2 when compared with 1 (at different days) with p-values shown in the table. This is in recognition with the statistics that Fluoroquinolones e.g., ciprofloxacin have known action against urinary pathogens including *Proteus mirabilis*¹⁷.

On comparing different groups with group 2, it was found that at day 5, highly significant results were shown by group 2 as compared to 3 and 4 with p-values 0.001 and 0.002, but at day 5 on comparing 2 with 5 the difference was not significant with p-value 0.089. The statistical difference on day 10

between 2 and 3 was 0.001 and between 3 and 4 was 0.034 which was significant. On the other hand comparison between 2 and 5 was not significant, p-values 0.226. The results were significant again on day 15 i.e. between group 2 and 3 p-values was 0.001 and 2 and 4 it was 0.037, and insignificant p-value 0.970 amongst group 2 and 5. These results propose

that Aloevera, in 25 ppm, showed no note worthy impact on bacterial count, but showed a reasonable antibacterial activity at intermediate dose. The results at highest dose i.e. 100ppm with p-value of 0.970 on last day exhibited that the effect was practically equivalent when compared with Ciprofloxacin (p-value 0.970).

P value comparison between the bacterial count of groups


Days	1 & 2	1 & 3	1 & 4	1&5	2&3	2&4	2&5	3&4	3&5	4&5
1	-	-	-	-	-	-	-	-	-	-
5	0.001 ***	0.596	0.130	0.002 ***	0.001 ***	0.002 ***	0.089	0.472	0.006 ***	0.010
10	<0.001 ***	0.089	0.001 ***	0.001 ***	0.002 ***	0.034*	0.226	0.151	0.013 **	0.496
15	<0.001 ***	0.049	0.001 ***	0.001 ***	0.001 ***	0.037 *	0.970	0.130	0.006 ***	0.151

*Significant

** More significant

*** Highly significant

Graph of bacterial count of five groups



CONCLUSION

In this study it was observed that, Aloevera extract in different doses for continuous 15 days showed mild, moderate and high antibacterial action that finally lead to the lowering of the bacterial count in urine and this effect was most marked on day 15th day of research with 100ppm. This may be suggestive that for the treatment of UTI caused by *Proteus mirabilis*, extract of Aloevera in high dose may offer an attractive and suitable alternative, although it takes extended time to express its effect. The results of this research undoubtedly show that Aloevera has encouraging properties especially against UTI and make this plant a promising agent to be explored further.

REFERENCES

1. Li X, Lockett CV, Johnson DE, Lane MC, Warren JW and Mobley HLT 2004. Development of an Intranasal Vaccine to Prevent Urinary Tract Infection by *Proteus mirabilis*. *Infect Immun*. 72(1): 66–75
2. Stuble K 2011. *Proteus Infections Treatment & Management* [homepage on the Internet]. Available from: <http://emedicine.medscape.com/article/226434-treatment> [Accessed 17th September 2010]
3. Kahlmeter G 2003. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. *J Antimicrob Chemother*; 51(1): 69-76
4. Khiljee S, Rehman N, Khiljee T, Ahmad RS, Khan MU, Qureshi UA 2011. Use of traditional herbal medicines

- in the treatment of eczema. *J of Pakistan Association of Dermatologists*; 21: 112-117
5. Kaur S 2010. Evaluation and improvement of Germplasm of Aloe Vera L from North India [Homepage on internet] Available from:
 6. http://shodhganga.inflibnet.ac.in/bitstream/10603/2340/8/08_chapter%202.pdf [Accessed on 20th September 2010]
 7. Lawrence R, Tripathi P, Jeyakumar E 2009 Isolation, Purification and Evaluation of Antibacterial Agents from Aloe Vera. *Brazilian J. of Microbiol*; 40: 906-915
 8. Shilpakala SR, Prathiba J, Malathi R 2009. Susceptibilities of *Escherichia coli* and *Staphylococcus aureus* to Aloe barbadensis. *European Review for Medical and Pharmacological Sciences*; 13: 461-464
 9. Mpala L, Chikowe G, Cock IE 2010. No evidence of antiseptic properties and low toxicity of selected Aloe species. *J. of Pharmaceutical Negative Results*; 1(1):10-16
 10. Cock IE 2011. Problems of Reproducibility and Efficacy of Bioassays Using Crude Extracts, with reference to Aloe vera: *Pharmacognosy Communications*; 1(1): 52-62
 11. Cowan MM, 1999 Plant Products as Antimicrobial Agents. *ClinMicrobiol Rev*; 12(4): 564-582
 12. Kadurugamuwa JL, Modi K, Yu J, Francis KP, Purchio T, Contag PR 2005. Noninvasive Biophotonic Imaging for Monitoring of Catheter-Associated Urinary Tract Infections and Therapy in Mice. *Infect Immun*; 73(7): 3878-3887
 13. Taiwo VO, Olukunle OA, Ozor IC, Oyejobi AT 2005. Consumption of aqueous extract of raw Aloe vera leaves: Histopathological and biochemical studies in rat and tilapia. *African J of Biomedical Res*; 8: 169-178
 14. Rivero NL, Legido JL, Santos IA, Casás LM 2012 Comparative Study of Microcalorimetric Behavior of *Escherichia Coli*, *Proteus Mirabilis* and *Klebsiella pneumonia*. *Pol J Microbiol* 2012; 61(3):199-204
 15. Johnson DE, Lockett CV, Russell RG, Hebel JR, Island MD, Stapleton A, Stamm WE, Warren JW 1998. Comparison of *Escherichia coli* Strains Recovered from Human Cystitis and Pyelonephritis Infections in Transurethrally Challenged Mice *Infect Immun*; 66(7): 3059–3065.
 16. Hvidberg H, Struve C, Karen A, Krogfelt KA, Christensen N, Rasmussen SN, Moller NF 2000. Development of a Long-Term Ascending Urinary Tract Infection Mouse Model for Antibiotic Treatment Studies. *Antimicrob. Agents Chemother*; 44(1): 1 156-163
 17. Cheesbrough M, 2003. *District laboratory practice in tropical countries*. 3rd ed., Cambridge, Cambridge University Press. pp113
 18. Navarro MDS, Marinero MLS, Navarro AS 2002. Pharmacokinetic/pharmacodynamic modelling of Ciprofloxacin 250 mg/12 h versus 500 mg/24 h for urinary infections. *J. Antimicrob. Chemother*; 50(1): 67-72.